Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial

Supplemental Digital Content is available in the text. Background and Purpose: The spectrum of brain infarction in patients with embolic stroke of undetermined source (ESUS) has not been well characterized. Our objective was to define the frequency and pattern of brain infarcts detected by magnetic resonance imaging (MRI) among patients with recent ESUS participating in a clinical trial. Methods: In the NAVIGATE ESUS trial (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source), an MRI substudy was carried out at 87 sites in 15 countries. Participants underwent an MRI using a specified protocol near randomization. Images were interpreted centrally by those unaware of clinical characteristics. Results: Among the 918 substudy cohort participants, the mean age was 67 years and 60% were men with a median (interquartile range) of 64 (26–115) days between the qualifying ischemic stroke and MRI. On MRI, 855 (93%) had recent or chronic brain infarcts that were multiple in 646 (70%) and involved multiple arterial territories in 62% (401/646). Multiple brain infarcts were present in 68% (510/755) of those without a history of stroke or transient ischemic attack before the qualifying ESUS. Prior stroke/transient ischemic attack (P<0.001), modified Rankin Scale score >0 (P<0.001), and current tobacco use (P=0.01) were associated with multiple infarcts. Topographically, large and/or cortical infarcts were present in 89% (757/855) of patients with infarcts, while in 11% (98/855) infarcts were exclusively small and subcortical. Among those with multiple large and/or cortical infarcts, 57% (251/437) had one or more involving a different vascular territory from the qualifying ESUS. Conclusions: Most patients with ESUS, including those without prior clinical stroke or transient ischemic attack, had multiple large and/or cortical brain infarcts detected by MRI, reflecting a substantial burden of clinical stroke and covert brain infarction. Infarcts most frequently involved multiple vascular territories. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909.

[1]  S. Connolly,et al.  Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. , 2020, JAMA neurology.

[2]  Thalia Shoshana Field,et al.  Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke , 2020, Stroke.

[3]  R. Sacco,et al.  Classification of Covert Brain Infarct Subtype and Risk of Death and Vascular Events. , 2019, Stroke.

[4]  H. Kamel,et al.  Tailoring the Approach to Embolic Stroke of Undetermined Source: A Review. , 2019, JAMA neurology.

[5]  S. Connolly,et al.  Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. , 2019, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[6]  D. Tanné,et al.  Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. , 2018, The Lancet. Neurology.

[7]  P. Rothwell,et al.  Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis , 2018, The Lancet Neurology.

[8]  S. Connolly,et al.  Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[9]  S. Connolly,et al.  Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source , 2018, The New England journal of medicine.

[10]  K. Hirao,et al.  Incidence of silent cerebral infarctions after catheter ablation of atrial fibrillation utilizing the second-generation cryoballoon , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  S. Connolly,et al.  Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update , 2017, Stroke.

[12]  Eric E. Smith,et al.  Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2017, Stroke.

[13]  J. Pogue,et al.  Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial , 2016, European stroke journal.

[14]  S. Connolly,et al.  Embolic strokes of undetermined source: the case for a new clinical construct , 2014, The Lancet Neurology.

[15]  D. Inzitari,et al.  Variation in Risk Factors for Recent Small Subcortical Infarcts With Infarct Size, Shape, and Location , 2013, Stroke.

[16]  Nick C Fox,et al.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.

[17]  R. D'Agostino,et al.  Prevalence and Correlates of Silent Cerebral Infarcts in the Framingham Offspring Study , 2008, Stroke.

[18]  P. Koudstaal,et al.  Silent brain infarcts: a systematic review , 2007, The Lancet Neurology.